Skip to main content
Premium Trial:

Request an Annual Quote

Celera to Develop Dxs for Merck Cancer Trials That Could Become Companion Tests

NEW YORK (GenomeWeb News) — Celera today said it will collaborate with Merck & Co. to develop molecular diagnostics for the drug maker to use in it clinical trials, which could potentially be used as companion diagnostics for Merck’s cancer drugs.
 
Terms of the deal, which is expected to wrap up at the end of Celera’s fiscal year 2008, call for the Applera unit to create assays based on gene-expression profiles that Merck identifies.
 
Celera said it will collect an undisclosed payment for its work in the collaboration, and will receive another payment if Merck opts to transfer one of Celera’s validated tests to a clinical reference lab, Celera said.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.